Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Levy, A.; Azria, D.; Pignon, J. P.; Delarochefordiere, A.; Martel-Lafay, I.; Rio, E.; Malka, D.; Conroy, T.; Miglianico, L.; Becouarn, Y.; Malekzadeh, K.; Leclercq, J.; Juzyna, B.; Ezra, P.; Lemanski, C.; Deutsch, E.. Radiother Oncol. 2015; 415-6: p.415-6
Article